OakChart

Inovio Pharmaceuticals Inc

INOHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:39 PM ET

1.42-0.03 (-1.81%)
2026-11-11 21:40 CET
Market cap
149.93 USD m
Revenue, TTM
0.30 USD m
Net income, TTM
-71.14 USD m
Free cash flow, TTM
-74.41 USD m
EPS diluted, TTM
-0.80
P/E
-
Compare

Price

INO against its 20, 50 and 200-day averages
2050200beatmiss
0.501.001.502.00111.1M222.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INOclose 1.4220-day 1.1450-day 1.18200-day 1.261.4252w low

47.6% under the 52-week high of 2.72 on 17 Dec 2025. 52-week low 0.56 on 30 Jul 2026. Last 15 sessions, 264.1% high to low

Volume 0.91× normal · the line is the 50-bar volume average

Profile

INO
52-week range, 40% of the way up
0.562.72

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Employees112
IPODec 08, 1998
Beta1.51
ATR, 14d0.25
Rel volume0.91
Short float21.46%
Insider own0.38%
Inst own39.18%

Snapshot

6 groups

Valuation

Index-
Market Cap147.21M
Enterprise Value106.13M
Income-71.14M
Sales0.30M
Book/sh-0.31
Cash/sh0.47
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees112
IPODec 08, 1998

Ratios

P/E-
Forward P/E-
PEG-
P/S490.70
P/B-
P/C3.04
P/FCF-
EV/EBITDA-
EV/Sales353.77
Quick Ratio0.57
Current Ratio0.57
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.80
EPS next Y-0.25
EPS next Q-0.14
EPS this Y55.06%
EPS next Y69.67%
EPS next 5Y61.91%
EPS past 3/5Y49.51% 32.44%
Sales past 3/5Y-81.47% -61.18%
EPS Y/Y TTM54.89%
Sales Y/Y TTM63.93%
EPS Q/Q42.79%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.-141.90% -

Ownership

Insider Own0.38%
Insider Trans0.00%
Inst Own39.18%
Inst Trans1.47%
ROA-109.84%
ROE-409.87%
ROIC-
Gross Margin-919.42%
Oper. Margin-25953.76%
Profit Margin-23798.90%
SMA2024.60%
SMA5020.62%
SMA20012.71%
Trades-

Technical

Shs Outstand110.18M
Shs Float103.01M
Short Float21.46%
Short Ratio2.04
Short Interest22.10M
52W High2.72 -47.66%
52W Low0.56 152.79%
Volatility17.21% 19.10%
ATR (14)0.25
RSI (14)55.38
Beta1.51
Rel Volume0.91
Avg Volume10.82M
Volume9,361,131

Performance

Perf Week-12.12%
Perf Month42.63%
Perf Quarter58.17%
Perf Half Y6.25%
Perf YTD-18.18%
Perf Year-28.82%
Perf 3Y-65.99%
Perf 5Y-98.36%
Perf 10Y-98.48%
Recom1.00
Target Price6.33
Prev Close1.45
Price1.42
Change %-1.81%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 02, 2026UpgradeHH.C. WainwrightNeutral → Buy$5+251.2%
Aug 13, 2026UpgradeJJefferiesHold → Buy$3+110.7%
Jul 09, 2025InitiatedPPiper SandlerOverweight$5+251.2%
May 14, 2024InitiatedSStephensOverweight$20+1,304.8%
Jan 25, 2024UpgradeOOppenheimerPerform → Outperform$4+181.0%
Nov 09, 2022DowngradeMMaxim GroupBuy → Hold
Nov 01, 2022DowngradeBBofA SecuritiesNeutral → Underperform$2+40.5%
Jul 19, 2022ResumedRRBC Capital MktsSector Perform$5 → $4+181.0%
May 11, 2022DowngradeOOppenheimerOutperform → Perform
Jan 21, 2022UpgradeBBofA SecuritiesUnderperform → Neutral$8 → $10+602.4%

Peers

Mkt cap
TickerCompanyMkt cap
PGENPrecigen Inc1.70B
PDSBPDS Biotechnology Corp105.26M
ARCTArcturus Therapeutics Holdings Inc270.21M
ENGNenGene Therapeutics Inc117.62M
MRNAModerna Inc101.16B
OCGNOcugen Inc321.66M
TNXPTonix Pharmaceuticals Holding Corp75.49M
ANIXAnixa Biosciences Inc98.04M
GNLXGenelux Corp85.97M
NVAXNovavax Inc1.64B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M

News

latest 14 of 100
  • INOVIO to Participate in Upcoming Investor Conferences (PR Newswire)
  • Inovio Misses On Normalized Loss, But VOCERYQ Approval And $80.5 Million Raise Reset The Story Around Launch Execution (Earnings Whispers)
  • Inovio: Q3 Earnings Snapshot (Associated Press)
  • INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights (PR Newswire)
  • Street Calls of The Week (Investing.com)
  • Inovio stock tumbles 25% on $75M share offering (Investing.com) -16.21%
  • INOVIO Announces Pricing of Approximately $75 Million Public Offering (PR Newswire) -10.49%
  • INOVIO Announces Proposed Public Offering of its Common Stock (PR Newswire)
  • Inovio's First Report After Its INO3107 Decision Date Puts Launch Readiness And Cash In Focus (Earnings Whispers) -12.17%
  • 4 Biotech Stocks Seeing Unusual Options Volume Today (Schaeffer's Research)
  • INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026 (PR Newswire) +213.75%
  • INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
  • Inovio shares surge 229% as FDA approves first commercial product (Proactive)
  • INOVIO Receives FDA Accelerated Approval for VOCERYQ to Reduce Surgery Frequency in Adults with RRP (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.500-0.207-0.4990.300.003
2026Q22026-08-12-0.070-0.217-0.0740.000.003
2026Q12026-05-13-0.280-0.350-0.2850.000.334
2025Q42026-03-120.060-0.3580.0550.000.005
2025Q32025-11-10-0.870-0.422-0.8720.000.006
2025Q22025-08-12-0.610-0.610-0.6060.000.016
2025Q12025-05-13-0.510-0.692-0.5100.070.015
2024Q42025-03-18-0.650-0.837-0.5970.120.046
2024Q32024-11-14-0.890-1.150-0.8940.000.116
2024Q22024-08-08-1.190-1.102-1.1850.100.136
2024Q12024-05-13-1.310-1.013-1.3080.000.166
2023Q42024-03-06-1.100-1.186-1.0970.100.365
2023Q32023-11-09-1.560-1.520-1.5160.390.123
2023Q22023-08-09-1.560-1.740-1.6130.230.284
2023Q12023-05-10-1.920-1.740-1.8880.110.284
2022Q42023-03-01-2.640-2.016-2.5460.130.345

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-14.520-12.703-14.5094.116.00
2020FY-12.840-13.815-12.8737.413.21
2021FY-17.400-15.000-17.4491.773.33
2022FY-14.040-13.296-14.07210.3010.55
2023FY-6.090-6.098-6.0940.831.06
2024FY-3.950-4.208-3.9490.220.13
2025FY-1.810-2.270-1.8100.070.09
2026FY--0.813--0.25
2027FY--0.247--64.88
2028FY--0.100--79.10
2029FY-0.270--157.3
2030FY-0.660--222.4

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-113100.050.000.15
2026Q4S2026-11-103010.000.000.00
2026Q4S2026-10-303010.000.000.00
2026Q4S2026-08-133000.670.002.00
2026Q4S2026-08-123000.670.002.00
2026Q4S2026-07-283010.670.002.00
2026Q4S2026-07-163020.670.002.00
2026Q4S2026-05-294028.610.0032.45
2026Q4S2026-05-274018.860.0032.45
2026Q4S2026-05-144028.860.0032.45
2026Q4S2026-03-183012.501.004.50
2026Q4S2026-03-133022.501.004.50
2026Q4S2026-01-283015.502.0010.00
2026Q4S2026-01-023115.502.0010.00

Estimate history

EPS, annual-13.08-12.574-14.509-12.873-17.449-14.072-6.094-3.949-1.812-0.8028
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.894-0.597-0.51-0.606-0.8720.055-0.285-0.074-0.499
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual42.2230.4824.1127.4111.77510.2620.8320.2180.0650.3
Period201720182019202020212022202320242025TTM
Sales, quarterly00.1170.065000000.299
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual7.538.1028.44715.57118.11521.09122.79336.168.997110.182
Period201720182019202020212022202320242025MRQ
Shares, quarterly26.05236.136.67436.71953.57268.99769.77382.342110.182
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.300.070.220.8310.261.777.414.1130.48
Cost of Goods Sold Incl. D&A3.052.993.133.505.504.73---
Gross Profit-2.75-2.92-2.91-2.674.77-2.96---
Selling, General and Administrative Excl. Other74.8383.90111.09132.56279.04308.26133.27116.00119.58
Research and Development44.4752.7977.2288.48194.35259.24100.6594.5995.26
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-77.58-86.82-114.00-135.23-274.27-311.22-130.48-117.41-94.09
Interest Expense0.000.000.181.221.251.948.707.950.00
Unusual Expense-12.55-1.61-4.894.667.853.2273.397.05-0.36
Net Income Before Taxes-71.14-84.95-107.25-135.12-277.65-303.22-162.89-120.81-94.80
Income Taxes0.000.000.000.000.000.000.00-0.262.17
Consolidated Net Income-71.14-84.95-107.25-135.12-279.82-303.66-167.47-120.55-96.97
Net Income From Continuing Operations-71.14-84.95-107.25-135.12-279.82-303.66-166.41-119.36-96.97
Net Income-71.14-84.95-107.25-135.12-279.82-303.66-166.41-119.36-96.97
EPS (Recurring)-0.81-1.84-4.07-5.95-13.80-17.32-8.90-13.91-12.61
EPS (Basic, Before Extraordinaries)-0.80-1.81-3.95-6.09-14.07-17.45-12.87-14.51-12.57
EPS (Diluted)-0.80-1.81-3.95-6.09-14.07-17.45-12.87-14.51-12.57
EBITDA-74.53-83.83-110.87-131.72-268.78-306.49-125.85-111.89-89.09
Non-Operating Income (Expense)-6.110.272.045.995.7213.1549.6811.60-1.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.083.706.4011.0722.5619.2311.427.158.42
Price To Sales Ratio402.581,248.52228.26163.1036.27587.16185.2479.2312.14
Gross Margin-919.42-4,474.06-1,337.41-321.0946.44-166.56---
Operating Margin-25,953.76-132,871.32-52,351.68-16,253.01-2,672.64-17,535.79-1,760.60-2,855.31-308.68
Net Margin-23,798.90-130,000.00-49,254.27-16,239.87-2,726.67-17,109.87-2,245.39-2,902.75-318.12
Shares Outstanding110.1869.0036.1022.7921.0918.1215.578.458.10
Market Capitalization149.93149.9366.06137.56389.201,084.741,653.64334.49388.90

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.300.000.000.000.000.000.070.12
Cost of Goods Sold Incl. D&A0.780.770.750.750.750.740.740.78
Gross Profit-0.48-0.77-0.75-0.75-0.75-0.74-0.68-0.66
Selling, General and Administrative Excl. Other19.0417.8621.2016.7220.4622.3424.3719.71
Research and Development10.3010.5013.759.9212.9814.1715.7212.89
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.52-18.62-21.95-17.48-21.21-23.08-25.05-20.37
Interest Expense0.000.000.000.000.00---
Unusual Expense26.81-13.96-4.22-21.1822.311.12-3.85-3.07
Net Income Before Taxes-49.20-6.01-19.683.76-45.50-23.52-19.69-19.38
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-49.20-6.01-19.683.76-45.50-23.52-19.69-19.38
Net Income From Continuing Operations-49.20-6.01-19.683.76-45.50-23.52-19.69-19.38
Net Income-49.20-6.01-19.683.76-45.50-23.52-19.69-19.38
EPS (Recurring)-0.31-0.19-0.33-0.16-0.57-0.59-0.58-0.66
EPS (Basic, Before Extraordinaries)-0.50-0.07-0.280.05-0.87-0.61-0.51-0.60
EPS (Diluted)-0.50-0.07-0.280.05-0.87-0.61-0.51-0.60
EBITDA-18.74-17.86-21.20-16.72-20.46-22.34-24.31-19.59
Non-Operating Income (Expense)-2.87-1.35-1.950.06-1.980.681.50-2.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.840.750.690.800.740.821.371.30
Price To Sales Ratio402.58--1,837.29669.50433.37222.33272.78
Gross Margin-161.51------1,037.77-563.14
Operating Margin-6,532.24------38,336.97-17,410.77
Net Margin-16,461.90------30,140.48-16,566.39
Shares Outstanding110.1882.3469.7769.0053.5736.7236.6736.10
Market Capitalization149.9390.50120.22119.54124.3574.6359.7766.06

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments58.5194.11145.29253.00401.31411.6489.5381.23127.43
Short Term Receivables0.001.202.4111.748.0319.062.034.056.49
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.612.525.4150.5139.1040.462.632.534.45
Total Current Assets61.1297.83153.11315.24448.44471.1794.2087.81138.36
Net Property, Plant & Equipment9.0711.7714.4517.9629.0224.0926.5615.9518.32
Total Investments and Advances2.101.612.782.013.914.896.329.4111.39
Intangible Assets--0.0012.6413.1413.6614.2115.2716.52
Deferred Tax Assets1.371.701.992.312.973.788.07--
Other Assets2.011.980.610.681.4325.962.672.672.64
Total Assets75.68114.90172.94350.85498.91543.55152.02131.11187.24
Short Term Debt Incl. Current Port. of LT Debt2.822.5019.182.802.602.332.070.000.00
Accounts Payable2.626.444.6521.0824.761.477.6511.028.49
Other Current Liabilities38.2326.3918.7472.9838.3837.9122.2724.2826.91
Total Current Liabilities43.6735.3342.5796.8765.7441.7131.9935.3035.41
Long Term Debt6.559.3711.0329.2730.4236.7297.430.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.371.701.992.353.003.818.100.020.02
Other Liabilities0.000.000.000.000.080.148.968.769.32
Total Liabilities51.5946.4055.60128.4999.2482.37146.4844.0844.75
Non-Equity Reserves0.000.000.000.000.000.040.140.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity24.1068.50117.35222.36399.67461.143.4486.94142.39
Total Shareholders Equity24.1068.50117.35222.36399.67461.143.4486.94142.39
Accumulated Minority Interest0.000.000.000.000.000.001.970.100.10
Total Equity24.1068.50117.35222.36399.67461.145.4087.03142.49
Total Liabilities & Stockholders Equity75.68114.90172.94350.85498.91543.55152.02131.11187.24
Book Value Per Share0.351.905.1510.5422.0629.620.4110.7318.91
Tangible Book Value Per Share0.351.905.159.9421.3428.74-1.288.8416.72
Full-Time Employees112134122184317262194281278
Price to Book Ratio27.320.651.001.462.713.5997.374.472.30
Return on Assets-89.14-74.52-51.59-65.86-58.26-47.85-84.31-60.92-48.87
Return on Equity-183.47-115.42-79.55-89.97-70.55-71.64-264.15-84.57-66.40
Return on Invested Capital-277.23-137.73-105.25-111.20-70.60-33.43-118.33-111.54-61.95
Quick Ratio1.402.773.603.256.8211.302.942.493.91
Current Ratio1.402.773.603.256.8211.302.942.493.91

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-71.14-84.95-107.25-135.12-279.82-303.66-167.47-120.55-96.97
Depreciation3.052.993.133.505.504.734.635.525.00
Other Funds (Non Cash)-4.912.552.7117.5434.2432.8755.9420.7213.71
Funds from Operations-73.00-79.41-101.41-114.11-236.05-266.06-106.91-94.31-78.26
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.28-9.22-2.66-10.2619.8350.35-71.07-3.544.71
Cash from Operating Activities-74.28-88.63-104.08-124.37-216.22-215.71-177.98-97.85-73.55
Capital Expenditures-0.13-0.29-0.49-0.32-0.97-1.23-1.52-0.99-2.09
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.066.220.000.002.382.96-
Purchase or Sale of Investments12.5814.33104.5081.46110.56-174.11-54.50-8.0644.50
Purchase of Investments-1.98-4.95-54.14-203.48-250.53-348.95-157.62-100.95-88.16
Sale Or Maturity of Investments14.5619.27158.64284.93361.08174.84103.1292.89132.66
Other Uses0.000.000.000.000.000.00-2.770.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities12.4514.04104.0787.36109.59-175.34-56.42-6.0842.42
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock72.4253.1668.315.4683.24216.11466.769.0931.04
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock72.4253.1668.315.4683.24216.11466.769.0931.04
Proceedsfrom Stock Options33.9734.9136.035.4682.96209.44454.499.0929.23
Issuance or Reduction of Debt, Net0.000.00-16.410.000.000.000.1794.130.00
Change in Long Term Debt0.000.000.000.000.000.000.1794.130.00
Issuance of Long Term Debt0.000.000.000.000.000.000.1797.440.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-3.310.00
Net Financing Active Other Cash Flow-0.19-0.11-0.42-0.47-1.40-4.61-4.03-0.780.00
Other Financing Activities Uses-0.19-0.11-0.42-0.47-1.40-4.61-4.03-0.780.00
Cash from Financing Activities72.2353.0551.485.0081.84211.50462.90102.4431.04
Exchange Rate Effect-0.000.03-0.00-0.03-0.030.03--
Net Change in Cash10.40-21.5451.50-32.02-24.81-179.58228.53-1.50-0.09
Free Cash Flow-74.41-88.92-104.56-124.69-217.18-216.94-179.50-98.84-75.64
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.00-0.034.030.000.000.010.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments48.3636.6737.6858.5150.8047.55
Short Term Receivables0.000.000.000.000.980.84
Inventories0.000.000.000.000.000.00
Other Current Assets3.083.241.762.613.404.31
Total Current Assets51.4439.9139.4461.1255.1852.70
Net Property, Plant & Equipment6.787.568.339.079.7010.45
Total Investments and Advances0.000.000.002.102.503.09
Deferred Tax Assets---1.37--
Other Assets1.921.922.012.012.012.01
Total Assets60.1449.3949.7875.6869.3968.24
Short Term Debt Incl. Current Port. of LT Debt2.692.902.912.822.742.66
Accounts Payable3.023.641.992.625.905.48
Other Current Liabilities83.7633.3833.0338.2361.1823.57
Total Current Liabilities89.4739.9237.9243.6769.8231.71
Long Term Debt4.595.105.796.557.288.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.37--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities94.0645.0243.7151.5977.1139.71
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-33.924.376.0724.10-7.7228.53
Total Shareholders Equity-33.924.376.0724.10-7.7228.53
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-33.924.376.0724.10-7.7228.53
Total Liabilities & Stockholders Equity60.1449.3949.7875.6869.3968.24
Book Value Per Share-0.310.050.090.35-0.140.78
Tangible Book Value Per Share-0.310.050.090.35-0.140.78
Full-Time Employees---112--
Price to Book Ratio27.3212.654.98-12.073.011.46
Return on Assets-109.84-114.64-123.95-89.14-122.52-86.88
Return on Equity--409.87-296.36-183.47-328.45-140.12
Return on Invested Capital--63.46-166.0412.29--64.38
Quick Ratio0.571.001.041.400.791.66
Current Ratio0.571.001.041.400.791.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-49.20-6.01-19.683.76-45.50-23.52
Depreciation0.780.770.750.750.750.74
Other Funds (Non Cash)28.94-12.63-1.14-20.0823.901.87
Funds from Operations-19.49-17.88-20.08-15.56-20.84-20.91
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.21-0.17-1.51-3.81-0.730.09
Cash from Operating Activities-15.27-18.05-21.59-19.37-21.57-20.81
Capital Expenditures0.000.000.00-0.13-0.07-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments3.726.152.640.078.945.31
Purchase of Investments0.000.99-2.980.000.00-4.95
Sale Or Maturity of Investments3.725.155.610.078.9410.26
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities3.726.152.64-0.068.875.28
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock26.9917.211.0827.1324.920.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock26.9917.211.0827.1324.920.00
Proceedsfrom Stock Options3.013.251.0826.627.190.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-0.06-0.130.00-0.00-0.03
Other Financing Activities Uses-0.00-0.06-0.130.00-0.00-0.03
Cash from Financing Activities26.9917.160.9527.1324.92-0.03
Exchange Rate Effect---0.000.000.00
Net Change in Cash15.445.25-18.007.7112.22-15.56
Free Cash Flow-15.27-18.05-21.59-19.50-21.64-20.84

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 217.76K 2025: 65.34K
United States2024: 217.76K 2025: 65.34K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.46%22.1M103.0M5.37M
2026-10-1520.68%21.3M103.0M4.02M
2026-09-3020.21%20.8M103.0M3.79M
2026-09-1519.34%19.9M103.0M3.60M
2026-08-3118.71%19.3M102.9M3.33M
2026-08-1419.40%20.0M102.9M3.04M
2026-07-3115.60%16.0M102.8M3.03M
2026-07-1517.79%14.6M81.9M2.34M
2026-06-3018.37%15.0M81.9M2.81M
2026-06-1519.79%16.2M81.9M2.68M
2026-05-2919.87%16.3M81.9M2.58M
2026-05-1519.52%16.0M81.9M2.30M
2026-04-3017.46%14.2M81.5M1.62M
2026-04-1515.66%12.8M81.5M1.54M
2026-03-3114.37%9.9M68.8M1.10M
2026-03-1315.64%10.8M68.8M1.39M
2026-02-2716.02%11.0M68.4M1.43M
2026-02-1316.69%11.4M68.4M1.46M
2026-01-3018.20%12.5M68.4M1.54M
2026-01-1517.09%11.7M68.4M1.54M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.751.050.9319.21331661.000.943-0.0410.000
call1.000.300.450.504.6797455.000.858-0.0350.000
call1.500.000.050.022.0052,9784510.389-0.0220.000
call2.000.000.050.054.8793,0392.000.209-0.0380.000
call2.500.000.050.036.6473,1890.000.170-0.0460.000
call3.000.000.650.008.1340.000.000.151-0.0510.000
call3.500.000.150.009.1670.000.000.140-0.0540.000
call4.000.000.050.259.65211.000.000.133-0.0510.000
put0.500.000.050.0512.66743.000.00-0.060-0.0390.000
put1.000.000.050.055.63639910.00-0.142-0.0340.000
put1.500.100.150.102.5211,848642-0.611-0.0220.000
put2.000.500.700.566.59315713.00-0.792-0.0380.000
put2.500.801.500.0016.5680.000.00-0.830-0.0440.000
put3.001.302.000.0018.1110.000.00-0.849-0.0490.000
put3.502.002.200.0010.7740.000.00-0.860-0.0540.000
put4.002.452.700.0011.6880.000.00-0.868-0.0570.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-05SEC
2026-11-06424B5SEC
2026-11-06FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05424B5SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-028-KCurrent report2026-10-30SEC
2026-10-068-KCurrent report2026-10-06SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-06SCHEDULE 13G/ASEC
2026-07-31SCHEDULE 13GSEC
2026-07-318-KCurrent report2026-07-29SEC
2026-07-30424B5SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-29424B5SEC
2026-07-10EFFECTEffectiveness filing by commission orderSEC
2026-07-02S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC16.27%
Jupiter Topco LLC6.29%
VANGUARD CAPITAL MANAGEMENT LLC4.44%
Boxer Capital Management, LLC3.46%
ADAR1 Capital Management, LLC2.61%
D. E. Shaw & Co., Inc.1.64%
TWO SIGMA INVESTMENTS, LP1.51%
Eversept Partners, LP1.26%
MILLENNIUM MANAGEMENT LLC0.97%
GEODE CAPITAL MANAGEMENT, LLC0.97%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.16%
Fidelity Small Cap Growth Fund2.33%
Fidelity Small Cap Growth K6 Fund1.22%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
iShares Micro-Cap ETF0.34%
Ultra-Small Company Fund0.21%
Fidelity Total Market Index Fund0.16%
Goldman Sachs Absolute Return Tracker Fund0.11%
Fidelity Series Total Market Index Fund0.11%
Invesco NASDAQ Future Gen 200 ETF0.08%

OakChart. INO. Cached 15 minutes.

Some panels did not load: insider.